From the Division of Transplant Surgery, Department of Surgery, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Exp Clin Transplant. 2022 Jul;20(7):702-705. doi: 10.6002/ect.2020.0073. Epub 2020 Nov 27.
Dyskeratosis congenita, a rare genetic disorder typified by progressive bone marrow failure, is classically characterized by the triad of abnormal skin pigmentation, nail dystrophy, and oral leukoplakia; however, it is a multisystem disease. Although hepatic involvement occurs in about 7% of patients with dyskeratosis congenita, end-stage liver disease is rare. Treatment of dyskeratosis congenita generally involves hematopoietic stem cell transplant. For patients with hepatic failure, liver transplant can be an option. Here, we describe a case of a patient with dyskeratosis congenita who presented with liver failure and pulmonary failure, precluding him from hematopoietic stem cell transplant. After liver transplant, the patient had significant improvements in pulmonary function and transfusion requirements, allowing the patient to qualify for hematopoietic stem cell transplant. Although hematopoietic stem cell transplant is typically the first step in the management of dyskeratosis congenita, for patients with severe hepatic manifestations of the disease, a liver transplant first approach may result in better disease management.
先天性角化不良症是一种罕见的遗传性疾病,其特征是进行性骨髓衰竭,经典表现为皮肤色素异常、指甲营养不良和口腔白斑三联征;然而,它是一种多系统疾病。虽然约 7%的先天性角化不良症患者存在肝脏受累,但终末期肝病很少见。先天性角化不良症的治疗一般包括造血干细胞移植。对于肝功能衰竭的患者,肝移植是一种选择。在这里,我们描述了一例先天性角化不良症患者,该患者因肝功能衰竭和呼吸衰竭而无法进行造血干细胞移植。肝移植后,患者的肺功能和输血需求显著改善,使患者有资格进行造血干细胞移植。虽然造血干细胞移植通常是先天性角化不良症治疗的第一步,但对于有严重肝脏表现的患者,肝移植首先可能会导致更好的疾病管理。